文献速递脊柱关节炎

银屑病关节炎强化生物制剂起始策略与标准升阶梯治疗对比(STAMP)

Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies.
PubMed 文献 · Lancet Rheumatol · 2025-11-20

STAMP研究是中英文双语标题的对照试验,在荷兰12家医院纳入120例新诊断、未使用过DMARDs的银屑病关节炎患者,随机接受早期司库奇尤单抗联合甲氨蝶呤或标准升阶梯治疗。12个月时两组临床改善相似,约半数患者达到ACR50。

要点

  • 12个月时两组临床改善相似,约半数患者达到ACR50。
  • 不良事件:早期强化组50%(30/60) vs 标准组53%(32/60);严重不良事件分别为10%(6/60)和8%(5/60);两组均无死亡。

核心结论

  • 在银屑病关节炎中,以司库奇尤单抗起始的强化达标治疗策略相比常规升阶梯达标治疗策略,未能在6个月时显著改善ACR50应答。
  • 至12个月时,两种策略带来相似的临床改善,约半数患者达到ACR50,提示无论初始治疗如何均可达到治疗目标。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在荷兰11家综合医院和1家学术医院进行。
  • 纳入120例新诊断银屑病关节炎患者(符合CASPAR标准,初诊时至少2个肿胀关节,未使用过任何DMARDs),随机1:1分配至早期司库奇尤单抗组(n=60)或标准治疗组(n=60)。

主要发现

  • 不良事件:早期司库奇尤单抗组30/60(50%) vs 标准治疗组32/60(53%);严重不良事件分别为6/60(10%)和5/60(8%);两组均无死亡。
  • 12个月时两种策略临床改善相似,约半数患者达到ACR50。

关键数值与推荐

  • 主要终点为意向治疗人群中6个月时ACR50应答比例。
  • 早期司库奇尤单抗组:皮下注射司库奇尤单抗300 mg(基线,之后每4周一次)联合每周口服甲氨蝶呤15 mg,最长12个月;未达最小疾病活动度(每3个月评估)时,依次换用TNF抑制剂、第二种TNF抑制剂,最后换用来氟米特。
  • 标准治疗组:每周口服甲氨蝶呤15 mg,6周时增至25 mg,最长12个月;未达最小疾病活动度时按标准治疗升阶梯。
  • 两组均在基线接受单次肌内注射甲泼尼龙80 mg。

临床怎么用

  • 对于新诊断且未使用过DMARDs的银屑病关节炎患者,早期使用司库奇尤单抗的强化达标治疗策略在6个月ACR50应答上未显著优于标准升阶梯达标治疗策略。
  • 两种策略在12个月时均可使约半数患者达到ACR50,临床可根据患者具体情况选择初始治疗策略。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treat-to-target strategies have previously been shown to improve outcomes in psoriatic arthritis. We aimed to evaluate whether a treat-to-target strategy using early intensive treatment with the IL-17A inhibitor secukinumab improves outcomes compared with a standard step-up treat-to-target approach in patients with psoriatic arthritis. METHODS: This multicentre, open-label, randomised controlled trial was done in 11 general hospitals and one academic hospital in the Netherlands. Eligible patients were aged 18 years or older with newly diagnosed psoriatic arthritis, fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria, had a minimum of two swollen joints at initial visit and were naive to any disease-modifying antirheumatic drugs. Participants were randomly assigned (1:1) to receive either early secukinumab treatment or standard of care. The early secukinumab group received subcutaneous secukinumab 300 mg at baseline and then every 4 weeks, plus weekly oral methotrexate 15 mg for a maximum of 12 months. If minimal disease activity (assessed at 3 month intervals) was not reached, secukinumab treatment was switched to a TNF inhibitor, followed by a second TNF inhibitor if necessary, and finally the second TNF inhibitor was stopped and treatment switched to apremilast. The standard of care group received weekly oral methotrexate 15 mg, escalating to 25mg at 6 weeks, for a maximum of 12 months. If minimal disease activity was not reached treatment was escalated according to standard of care. Patients in both groups also received a single intramuscular injection of methylprednisolone 80 mg at baseline. The primary outcome was the proportion of patients with an ACR50 response at 6 months in the intention-to-treat population. The safety set included all patients who received at least one dose of study treatment. People with lived experience of psoriatic arthritis were involved in the study design. This trial was registered with ISRCTN (ISRCTN76054545). FINDINGS: Between Dec 19, 2019, and Oct 19, 2023, 130 patients were screened for eligibilty and 120 patients were enrolled and randomly assigned to receive either early secukinumab treatment (n=60) or standard of care (n=60). Across the two groups, 49 (41%) of 120 patients were female, 71 (59%) were male, and the mean age was 49 years (SD 15). Of the 110 patients for whom ethnicity data were available, 108 (98%) were of Dutch origin. At month 6, ACR50 was reported in 25 (42%) of 60 patients in the early secukinumab group and 21 (35%) of 60 patients in the standard of care group (relative risk 1·19, 95% CI 0·75-1·88; p=0·45); thus, the primary outcome was not met. Adverse events occurred in 30 (50%) of 60 patients in the early secukinumab group and 32 (53%) of 60 patients in the standard of care group. Serious adverse events were reported in six (10%) patients in the early secukinumab group and five (8%) in the standard of care group. No deaths occurred in either group. INTERPRETATION: Early use of intensive treatment with secukinumab in a treat-to-target strategy did not result in statistically superior outcomes compared with a conventional step-up treat-to-target approach. By month 12, both strategies led to similar clinical improvements, with half of patients attaining ACR50, suggesting that treatment targets can be met regardless of initial therapy. FUNDING: Novartis.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Koc GH, Kok MR, Kasiem FR, et al. Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies. Lancet Rheumatol. 2025. PMID: 41275881. doi:10.1016/S2665-9913(25)00223-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。